中医科

订阅

MedSci主页 / 所有栏目 / 中医科

46家单位入选！国家中医药传承创新中心公示

2022-03-31 国家中医药管理局 国家中医药管理局

国家中医药传承创新中心
关注

国家中医药传承创新中心建设单位名单包括首都医科大学附属北京中医医院、上海中医药大学附属龙华医院、广州中医药大学第一附属医院等。

关于国家中医药传承创新中心拟入库单位名单公示的公告

根据国家中医药传承创新中心总体工作安排与《国家中医药传承创新中心建设项目遴选工作办法》有关要求，经综合评审，我局与国家发展改革委会商确定了国家中医药传承创新中心拟入库单位名单，现予以公示，公示时间为2022年3月29日至4月4日。

公示期内若有异议，请以书面形式向国家中医药传承创新中心遴选工作办公室反映(信函以到达日邮戳为准)。以单位名义反映情况的材料需加盖单位公章，以个人名义反映情况的材料要署本人真实姓名并提供联系方式。

联系电话：010-59957709;010-59957708

电子邮箱：zhyc@natcm.gov.cn

通信地址：北京市东城区工体西路1号国家中医药管理局科技司

邮编：100027

国家中医药传承创新中心遴选工作办公室

2022年3月29日

附件1

国家中医药传承创新中心建设单位名单

附件2

国家中医药传承创新中心培育单位名单

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796823, encodeId=10911e968235d, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Aug 12 12:00:04 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675597, encodeId=e16c16e559729, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Dec 23 13:00:04 CST 2022, time=2022-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286077, encodeId=313b12860e76c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410207, encodeId=c460141020e89, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-08-12 李研东

    #中医药传承创新#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1796823, encodeId=10911e968235d, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Aug 12 12:00:04 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675597, encodeId=e16c16e559729, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Dec 23 13:00:04 CST 2022, time=2022-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286077, encodeId=313b12860e76c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410207, encodeId=c460141020e89, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-12-23 lishizhe

    #传承#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1796823, encodeId=10911e968235d, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Aug 12 12:00:04 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675597, encodeId=e16c16e559729, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Dec 23 13:00:04 CST 2022, time=2022-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286077, encodeId=313b12860e76c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410207, encodeId=c460141020e89, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-04-02 lilianxiang

    #创新#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1796823, encodeId=10911e968235d, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Aug 12 12:00:04 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675597, encodeId=e16c16e559729, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Dec 23 13:00:04 CST 2022, time=2022-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286077, encodeId=313b12860e76c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410207, encodeId=c460141020e89, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 02 00:00:04 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-04-02 cathymary

    #医药#

    0